DTI Lifts Trade Ban on AEROGIN and RELX, FLARE and Others Still Need PS Certification

Nov.26.2024
DTI Lifts Trade Ban on AEROGIN and RELX, FLARE and Others Still Need PS Certification
The Philippine Department of Trade and Industry (DTI) has lifted the trade ban on AEROGIN and RELX, while products from brands like FLARE, NIXX, and VAPENGIN still require Philippine Standards (PS) certification before they can be sold.

The Department of Trade and Industry (DTI) has officially lifted the suspension on the sale of vape products produced by AEROGIN and RELX.

 

At the same time, the DTI has removed the Preliminary Order/Preventive Measure Order against FLARE, NIXX, and VAPENGIN products. However, the sale of these products will remain prohibited until they secure the necessary Philippine Standard (PS) certification.

 

DTI emphasizes its commitment to ensuring the safety and quality of vape products in the Philippine market through strict enforcement of regulatory standards. Under Republic Act No. 11900 (RA11900), also known as the "Vaporized Nicotine and Non-Nicotine Products Regulation Act," and related regulations, the Office for the Special Mandate on Vaporized Nicotine and Non-Nicotine Products (OSMV) has the authority to take immediate action, including the recall, restriction, or confiscation of non-compliant vape products, devices, or novel tobacco products, following due process.

Global Forum on Nicotine 2026 to explore why prohibition of safer nicotine products risks, and does not protect, public health
Global Forum on Nicotine 2026 to explore why prohibition of safer nicotine products risks, and does not protect, public health
Mar.12
U.S. Company Seeks Cancellation of “Lost Mary” Vape Trademark
U.S. Company Seeks Cancellation of “Lost Mary” Vape Trademark
North Carolina hemp provider JLT Imports Inc. has filed suit in California federal court seeking cancellation of the “Lost Mary” vape trademark held by Chinese company Imiracle (HK) Ltd.
Mar.30 by 2FIRSTS.ai
Imperial Brands Forms Global AI Partnership with Capgemini, Reinforcing Artificial Intelligence as Core Infrastructure in the Nicotine Industry
Imperial Brands Forms Global AI Partnership with Capgemini, Reinforcing Artificial Intelligence as Core Infrastructure in the Nicotine Industry
Industry Insight
Feb.19
Spain’s Nicotine Pouch Sales Reached 5 Million Cans in 2025, Industry Says 2026 Could Hit 8 Million
Spain’s Nicotine Pouch Sales Reached 5 Million Cans in 2025, Industry Says 2026 Could Hit 8 Million
Spain’s Nicotine Pouch Association said nicotine pouch sales in Spain reached 5 million cans of 20 units in 2025 and are expected to rise 60% to 8 million in 2026. The group said there are currently 20 to 30 brands on the Spanish market and called for regulation proportionate to product risk. It also opposed a proposal to reduce nicotine content to 0.99 mg per pouch, saying it would amount to a de facto ban on the category.
Mar.19 by 2FIRSTS.ai
Nebraska Lawmakers Consider Major Tax Hikes on Cigarettes, Vapes and Other Nicotine Products
Nebraska Lawmakers Consider Major Tax Hikes on Cigarettes, Vapes and Other Nicotine Products
Nebraska lawmakers are considering two tax bills targeting nicotine products. LB1124 would raise the cigarette tax from $0.64 to $1.64 per pack, while LB1238 would shift cigarettes to a 30% tax on the retailer’s purchase price and increase taxes on alternative nicotine and other tobacco products to 30%. The commentary argues the hikes could raise consumer costs, pressure small retailers, and increase cross-border shopping and illicit market activity.
Feb.04 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11